CN110227157A - 掺钆硅纳米粒子/光敏剂自组装金属有机框架纳米材料的制备方法 - Google Patents
掺钆硅纳米粒子/光敏剂自组装金属有机框架纳米材料的制备方法 Download PDFInfo
- Publication number
- CN110227157A CN110227157A CN201910541710.8A CN201910541710A CN110227157A CN 110227157 A CN110227157 A CN 110227157A CN 201910541710 A CN201910541710 A CN 201910541710A CN 110227157 A CN110227157 A CN 110227157A
- Authority
- CN
- China
- Prior art keywords
- dox
- nano
- fzif
- silicon nano
- gadolinium silicon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AABGKKDTOXGNDF-UHFFFAOYSA-N [Si].[Gd] Chemical compound [Si].[Gd] AABGKKDTOXGNDF-UHFFFAOYSA-N 0.000 title claims abstract description 100
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 88
- 239000002184 metal Substances 0.000 title claims abstract description 88
- 238000002360 preparation method Methods 0.000 title claims abstract description 75
- 239000003504 photosensitizing agent Substances 0.000 title claims abstract description 64
- 239000002086 nanomaterial Substances 0.000 title claims abstract description 50
- 238000001338 self-assembly Methods 0.000 title claims description 56
- 238000003745 diagnosis Methods 0.000 claims abstract description 69
- 230000010354 integration Effects 0.000 claims abstract description 67
- 238000002156 mixing Methods 0.000 claims abstract description 49
- 239000002105 nanoparticle Substances 0.000 claims abstract description 48
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 25
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 25
- 238000006243 chemical reaction Methods 0.000 claims abstract description 12
- 238000012986 modification Methods 0.000 claims abstract description 12
- 230000004048 modification Effects 0.000 claims abstract description 12
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920000642 polymer Polymers 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 9
- -1 dimethylaminoethyl Chemical group 0.000 claims abstract description 9
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 4
- 239000013110 organic ligand Substances 0.000 claims abstract description 4
- 239000004698 Polyethylene Substances 0.000 claims abstract description 3
- 229920000573 polyethylene Polymers 0.000 claims abstract description 3
- 230000004043 responsiveness Effects 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims description 38
- 229960002918 doxorubicin hydrochloride Drugs 0.000 claims description 38
- 239000008367 deionised water Substances 0.000 claims description 26
- 229910021641 deionized water Inorganic materials 0.000 claims description 26
- 229910001868 water Inorganic materials 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 239000006185 dispersion Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 claims description 7
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 7
- 229960003330 pentetic acid Drugs 0.000 claims description 7
- 239000001509 sodium citrate Substances 0.000 claims description 7
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 7
- 229940038773 trisodium citrate Drugs 0.000 claims description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 6
- 229910003317 GdCl3 Inorganic materials 0.000 claims description 6
- MEANOSLIBWSCIT-UHFFFAOYSA-K gadolinium trichloride Chemical compound Cl[Gd](Cl)Cl MEANOSLIBWSCIT-UHFFFAOYSA-K 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 235000007164 Oryza sativa Nutrition 0.000 claims description 4
- 235000009566 rice Nutrition 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 3
- 229910052786 argon Inorganic materials 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000007789 gas Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 238000005034 decoration Methods 0.000 claims 1
- 238000002242 deionisation method Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 13
- 229920002246 poly[2-(dimethylamino)ethyl methacrylate] polymer Polymers 0.000 abstract description 10
- 239000011724 folic acid Substances 0.000 abstract description 5
- 230000002902 bimodal effect Effects 0.000 abstract description 4
- 238000003384 imaging method Methods 0.000 abstract description 4
- 230000008685 targeting Effects 0.000 abstract description 3
- 238000013267 controlled drug release Methods 0.000 abstract 1
- 229960000304 folic acid Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 description 46
- 238000012512 characterization method Methods 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000013154 zeolitic imidazolate framework-8 Substances 0.000 description 6
- MFLKDEMTKSVIBK-UHFFFAOYSA-N zinc;2-methylimidazol-3-ide Chemical compound [Zn+2].CC1=NC=C[N-]1.CC1=NC=C[N-]1 MFLKDEMTKSVIBK-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229940064302 folacin Drugs 0.000 description 4
- 235000019152 folic acid Nutrition 0.000 description 4
- 210000005075 mammary gland Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- 239000012621 metal-organic framework Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000000370 laser capture micro-dissection Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- DPBJAVGHACCNRL-UHFFFAOYSA-N 2-(dimethylamino)ethyl prop-2-enoate Chemical compound CN(C)CCOC(=O)C=C DPBJAVGHACCNRL-UHFFFAOYSA-N 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000013105 nano metal-organic framework Substances 0.000 description 1
- 239000013289 nano-metal-organic framework Substances 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000013384 organic framework Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1854—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
- A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
一种掺钆硅纳米粒子/Ce6光敏剂自组装多功能诊疗一体化金属有机框架纳米材料(FZIF‑8/DOX‑PD‑FA)的制备方法,以2‑甲基咪唑为有机配体和Zn2+为金属离子,将掺钆硅(Si‑Gd)纳米粒子和Ce6光敏剂加入反应体系一锅法快速合成多功能诊疗一体化金属有机框架纳米粒子,表面修饰pH响应性PDMAEMA(聚甲基丙烯酸二甲氨基乙酯)线性聚合物用于实现肿瘤微酸环境下的可控药物释放,进一步修饰MaL‑PEG‑FA(聚乙二醇‑叶酸)实现对MCF‑7肿瘤的靶向性。本发明制备的FZIF‑8/DOX‑PD‑FA纳米粒子可在荧光/磁共振双模态成像指导下对MCF‑7肿瘤实现化学光动力综合性治疗。
Description
技术领域
本发明属于纳米材料的制备领域,特别是一种掺钆硅纳米粒子/光敏剂Ce6自组装的多功能诊疗一体化金属有机框架纳米材料的制备方法。
背景技术
目前,纳米金属有机框架材料(MOFs)作为具有高药物载量的药物纳米载体备受关注,这主要是因为MOFs具备较大的孔体积,大的比表面积和孔径易于调节的特点。沸石咪唑骨架材料(ZIF-8)作为MOFs的一种,它具有很好的热稳定性。同时,它无毒且具有良好的生物相容性,以及在酸性条件下可以降解,所以ZIF-8是一种良好的药物载体。现如今,对作为药物载体的ZIF-8纳米材料研究发展甚多,但是由于该纳米材料自身存在的不足,无法实现对目标肿瘤的多功能诊疗一体化,因此很大程度限制了它的发展。参见:H.Y.Zhang,W.Jiang,R.L.Liu,J.Zhang,D.Zhang,Z.H.Li,Y.X.Luan,ACS Appl.Mater.Interfaces,2017,9,19687-19697;H.Q.Zheng,Y.N.Zhang,L.F.Liu,W.Wan,P.Guo,A.M.Nystrom,X.D.Zou,J.Am.Chem.Soc.,2016,138,962-968;L.Y.Chen,Y.Peng,H.Wang,Z.Z.Gu,C.Y.Duan,Chem.Commun.,2014,50,8651-8654.掺钆的硅纳米粒子(Si-GdNPs)不仅具有优良的光学性质,无毒且生物相容性好,还可以实现荧光及磁共振双模态成像。参见:H.L.Ye,S.J.Cai,S.Li,X.W.He,W.Y.Li,Anal.Chem.,2016,88,11631-11638;Y.K.Dou,Y.Chen,X.W.He,W.Y.Li,Y.H.Li,Y.K.Zhang,Anal.Chem.,2017,89,11286-11292;S.Li,F.Wang,X.W.He,W.Y.Li,Y.K.Zhang,J.Mater.Chem.B,2018,6,3358-3365.二氢卟吩e6(Ce6)光敏剂通过近红外光照射会产生单线态氧,对肿瘤可以实现光动力治疗。L.H.Wu,X.J.Cai,H.F.Zhu,J.H.Li,D.X.Shi,D.F.Su,D.Yue,Z.W.Gu,Adv.Funct.Mater.,2018,28,1804324;W.L.Wang,L.Lin,X.J.Ma,B.Wang,S.R.Liu,X.X.Yan,S.R.Li,H.Y.Tian,X.F.Yu,ACSAppl.Mater.Interfaces,2018,10,19398-19407.多功能纳米粒子可实现诊疗一体化的优势是单纯的ZIF-8无法实现的。现如今还没有基于Si-GdNPs、光敏剂与ZIF-8一体化的金属有机框架材料。鉴于Si-GdNPs优良的荧光/磁共振成像性能及Ce6在近红外光照射下产生单线态氧用于癌症治疗的性能,将ZIF-8,Si-Gd NPs和Ce6相结合开发一种简单的方法用于合成,可实现诊疗一体化的、具备靶向性的多功能金属有机框架纳米粒子迫在眉睫。
发明内容
本发明目的在于针对上述技术存在的不足和问题,提供了一种掺钆硅纳米粒子/光敏剂Ce6自组装的多功能诊疗一体化金属有机框架纳米材料的制备方法。以2-甲基咪唑为有机配体和Zn2+为金属离子,将Si-Gd纳米粒子和Ce6光敏剂加入反应体系一锅法快速合成金属有机框架纳米粒子。所制备的诊疗一体化金属有机框架纳米粒子对叶酸受体过表达癌细胞的识别具有很好的特异性和选择性;且制备方法简单,在荷瘤小鼠的活体实验中,证明了该纳米材料可实现荧光/磁共振双模态成像指导的化学/光动力综合性治疗,同时,在实际药物的靶向递送中对目标肿瘤细胞的选择性识别和给药治疗有着良好的应用前景。
本发明的技术方案:
一种掺钆硅纳米粒子/Ce6光敏剂自组装的多功能诊疗一体化金属有机框架纳米材料的制备方法,以2-甲基咪唑为有机配体和Zn2+为金属离子,将掺钆硅(Si-Gd)纳米粒子和Ce6光敏剂加入反应体系快速一锅法合成多功能诊疗一体化金属有机框架纳米粒子,负载药物后,在其表面修饰pH响应性PDMAEMA线性聚合物,再在表面修饰MaL-PEG-FA,包括如下步骤:
1)掺钆硅纳米粒子的制备,将柠檬酸三钠、二乙三胺五乙酸与GdCl3.H2O溶解在去离子水中,氩气保护下搅拌10-20min,加入3-氨丙基三乙氧基硅烷(APTES)继续剧烈搅拌20-30min,将反应物转移至反应釜中放入180-200℃烘箱,2-3h后得到掺钆硅纳米粒子;
2)掺钆硅纳米粒子的纯化,待上述反应产物降至室温,向掺钆硅纳米粒子中加入稀盐酸,将稀释后的产物转移至透析袋透析过夜,得到纯化的掺钆硅纳米粒子(Si-GdNPs)溶液;
3)将纯化的掺钆硅纳米粒子用去离子水稀释,加入25mg/mL的聚乙烯吡咯烷酮-k30(PVP),在室温下反应12-24h,离心浓缩,制得PVP修饰的掺钆硅纳米粒子(Si-Gd@PVP);
4)将制备得到的Si-Gd@PVP溶液加入到ZnNO3甲醇溶液中,再将2-甲基咪唑溶液和Ce6溶液加入上述反应混合溶液中,磁力剧烈搅拌60-90min,离心,用甲醇和水清洗得到掺钆硅纳米粒子/Ce6掺杂的金属有机框架双荧光纳米粒子(FZIF-8);
5)将制备的FZIF-8纳米粒子加入盐酸阿霉素(DOX)溶液中吸附完全,清洗三次,得到负载有DOX的荧光金属有机框架纳米粒子(FZIF-8/DOX);
6)将制备的FZIF-8/DOX纳米粒子分散在去离子水中,加入制备好的聚甲基丙烯酸二甲氨基乙酯线性聚合物(PDMAEMA),室温条件下搅拌12-24h,用去离子水清洗三次得到PDMAEMA修饰的荧光金属有机框架纳米材料(FZIF-8/DOX-PD);
7)将制备的FZIF-8/DOX-PD纳米粒子分散在去离子水中,加入MaL-PEG-FA溶液,用氢氧化钠调节反应体系为pH=8.5,磁力搅拌反应8-12h,用去离子水清洗三次,得到MaL-PEG-FA修饰的双荧光诊疗一体化金属有机框架纳米材料(FZIF-8/DOX-PD-FA)。
步骤1)所述柠檬酸三钠、二乙三胺五乙酸、GdCl3.H2O、3-氨丙基三乙氧基硅烷用量比为:0.4-0.42g:0.3-0.32g:0.2-0.22g:2-2.2mL。
步骤2)所述掺钆硅纳米粒子溶液与盐酸体积比例为:8mL:6-7mL,所述盐酸的浓度为1mol/L。
步骤3)所述纯化的掺钆硅纳米粒子溶液、聚乙烯吡咯烷酮-k30(PVP)体积比例为:10-12mL:4-6mL。
步骤4)所述ZnNO3溶液、2-甲基咪唑溶液、Si-Gd@PVP溶液、Ce6溶液的体积比例为:30-31mL:30mL:0.5-6mL:0.2-3mL,所述ZnNO3溶液浓度为14.6mg/mL,2-甲基咪唑溶液浓度为32.4mg/mL。
步骤5)所述掺钆硅纳米粒子/Ce6掺杂的金属有机框架荧光纳米粒子(FZIF-8)、DOX溶液比例为:2mg:5-10mL,所述DOX的浓度为0.2mg/mL。
步骤6)所述负载有DOX的双荧光金属有机框架纳米粒子(FZIF-8/DOX)与聚甲基丙烯酸二甲氨基乙酯线性聚合物(PDMAEMA)的比例为50mg:5-10mg。
步骤7)所述FZIF-8/DOX-PD纳米粒子与MaL-PEG-FA的比例为:50mg:6-10mg。
本发明的优点和有益效果:
1)掺钆硅纳米粒子作为一种新型纳米材料,同时兼具荧光和高比表面积的优良特性,应用于金属有机框架纳米粒子的制备过程中可以使得所制备的纳米颗粒具有优良的荧光及磁共振性质;
2)制备金属有机框架纳米粒子过程中,除了掺杂掺钆硅纳米粒子同时也掺杂了Ce6光敏剂,使得金属有机框架纳米粒子具有双色荧光;
3)所制备的金属有机框架纳米粒子具有介孔结构可以负载药物,以及Ce6可以在近红外光照下产生单线态氧,使得该纳米粒子可以实现双模态治疗;
4)该纳米粒子表面修饰有PDMAEMA可以防止药物泄漏,再者修饰有MaL-PEG-FA,在增强生物相容性的同时也实现了靶向成像和靶向治疗。
附图说明
图1是负载有DOX的诊疗一体化金属有机框架纳米材料(FZIF-8/DOX-PD-FA)的透射电镜图。
图2是诊疗一体化金属有机框架纳米材料(FZIF-8/DOX-PD-FA)(40μg/mL,4h)对MCF-7乳腺癌细胞特异性识别的激光显微共聚焦图。(FZIF-8/DOX是无靶向纳米粒子以及A549是叶酸受体阴性表达的细胞作为对照组,蓝色是Si-GdNPs,黄色是Ce6,红色是DOX)。
图3是FZIF-8/DOX-PD-FA+NIR对长有MCF-7乳腺实体瘤小鼠的治疗效果图(PBS、DOX、FZIF-8-PD-FA+NIR、FZIF-8/DOX-PD-FA作为对照组),图中显示:FZIF-8/DOX-PD-FA+NIR对目标MCF-7乳腺实体瘤有最好的治疗效果。
具体实施方式
实施例1:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,具体包括如下步骤:
1)掺钆硅纳米粒子的制备,将0.4g柠檬酸三钠、0.3g二乙三胺五乙酸与0.2gGdCl3.H2O溶解在8mL去离子水中,氩气保护下剧烈搅拌20min,加入2mL 3-氨丙基三乙氧基硅烷(APTES)继续剧烈搅拌30min放入反应釜中进行反应,200℃,3h后得到掺钆硅纳米粒子;
2)掺钆硅纳米粒子的纯化,向8mL掺钆硅纳米粒子中加入6mL浓度为1mol/L的稀盐酸,透析过夜,得到纯化的掺钆硅纳米粒子(Si-GdNPs)溶液;
3)将纯化的10mL掺钆硅纳米粒子加入到去离子水中,加入4mL(25mg/mL)的聚乙烯吡咯烷酮-k30(PVP),在室温下反应24h,离心浓缩,制得PVP修饰的掺钆硅纳米粒子(Si-Gd@PVP);
4)将制备得到的2mL Si-Gd@PVP溶液加入到30mLZnNO3甲醇溶液中,再将30mL2-甲基咪唑溶液和0.2mLCe6溶液加入上述反应混合溶液中,磁力剧烈搅拌60min,离心,用甲醇和水清洗得到掺钆硅纳米粒子/Ce6自组装的金属有机框架荧光纳米粒子(FZIF-8);
5)将制备的2mgFZIF-8纳米粒子加入5mL盐酸阿霉素(DOX)吸附完全,清洗三次,得到负载有DOX的荧光金属有机框架纳米粒子(FZIF-8/DOX);
6)将制备的50mgFZIF-8@DOX纳米粒子分散在去离子水中,加入制备好的5mg聚甲基丙烯酸二甲氨基乙酯线性聚合物(PDMAEMA),室温条件下搅拌24h,用去离子水清洗三次得到PDMAEMA修饰的多功能诊疗一体化金属有机框架纳米材料(FZIF-8/DOX-PD);
7)将制备的50mg FZIF-8/DOX-PD纳米粒子分散在去离子水中,加入MaL-PEG-FA(6mg),用氢氧化钠调节反应体系为pH=8.5,磁力搅拌反应12h,用去离子水清洗三次,得到PEG-FA修饰的双荧光金属有机框架纳米材料(FZIF-8/DOX-PD-FA)。
图1是负载有DOX的诊疗一体化金属有机框架纳米材料(FZIF-8/DOX-PD-FA)的透射电镜图。图中显示:粒径大小约为80nm。
图2是诊疗一体化金属有机框架纳米材料(FZIF-8/DOX-PD-FA)(40μg/mL,4h)对MCF-7乳腺癌细胞特异性识别的激光显微共聚焦图。(FZIF-8/DOX是无靶向纳米粒子,A549是叶酸受体阴性表达的肿瘤细胞作为对照组,蓝色是Si-GdNPs,黄色是Ce6,红色是DOX)。图中显示:所制备FZIF-8/DOX-PD-FA对目标叶酸受体过表达MCF-7乳腺癌细胞有特异性识别靶向性,相比于FZIF-8/DOX和A549细胞,FZIF-8/DOX-PD-FA进入到MCF-7细胞内部的纳米粒子更多。
图3是FZIF-8/DOX-PD-FA+NIR对长有MCF-7乳腺实体瘤小鼠的治疗效果图(PBS、DOX、FZIF-8-PD-FA+NIR、FZIF-8/DOX-PD-FA作为对照组),图中显示:FZIF-8/DOX-PD-FA+NIR对目标MCF-7乳腺实体瘤有最好的治疗效果。
实施例2:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤1)取0.42g柠檬酸三钠加入到8mL去离子水中。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例3:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤1)取0.32g二乙三胺五乙酸加入8mL去离子水中。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例4:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤2)掺钆硅纳米粒子的纯化,将8mL掺钆硅纳米粒子加入7mL(1mol/L)稀盐酸。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例5:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤3)向10ml纯化后的掺钆硅纳米粒子溶液加入6mL(25mg/ml)的聚乙烯吡咯烷酮-k30。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例6:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤4)将2mL Ce6溶液加入反应混合溶液中。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例7:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤4)将3mL Ce6溶液加入反应混合溶液中。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例8:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤4)将4mL Ce6溶液加入反应混合溶液中。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例9:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤5)2mg FZIF-8纳米粒子加入6mL盐酸阿霉素(DOX)吸附完全。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例10:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤5)2mg FZIF-8纳米粒子加入8mL盐酸阿霉素(DOX)吸附完全。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例11:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤6)50mg FZIF-8/DOX纳米粒子分散在去离子水中,加入制备好的8mg聚甲基丙烯酸二甲氨基乙酯线性聚合物(PDMAEMA)。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例12:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤6)50mg FZIF-8/DOX纳米粒子分散在去离子水中,加入制备好的10mg聚甲基丙烯酸二甲氨基乙酯线性聚合物(PDMAEMA)。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例13:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤7)将制备的50mgFZIF-8/DOX-PD纳米粒子分散在去离子水中,加入MaL-PEG-FA(8mg)。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例14:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤7)将制备的50mgFZIF-8/DOX-PD纳米粒子分散在去离子水中,加入MaL-PEG-FA(10mg)。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例15:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤1)将2.2mLAPTES加入8mL的去离子水中。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例16:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤1)将0.22mL GdCl3.H2O加入8mL的去离子水中。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例17:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤3)向12ml纯化后的掺钆硅纳米粒子溶液加入6mL(25mg/ml)的聚乙烯吡咯烷酮-k30。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例18:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤3)向12ml纯化后的掺钆硅纳米粒子溶液加入4mL(25mg/ml)的聚乙烯吡咯烷酮-k30。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同
实施例19:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤1)取0.41g柠檬酸三钠加入到8mL去离子水中。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例20:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤1)取0.31g二乙三胺五乙酸加入8mL去离子水中。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例21:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤1)将0.21mL GdCl3.H2O加入8mL的去离子水中。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
实施例22:
一种掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料的制备方法,合成步骤与实施例1基本相同,不同之处在于:步骤1)将2.1mLAPTES加入8mL的去离子水中。
最终制备掺钆硅纳米粒子/光敏剂Ce6自组装的诊疗一体化金属有机框架纳米材料表征及FZIF-8/DOX-PD-FA应用结果与实施例1类同。
Claims (8)
1.一种掺钆硅纳米粒子/Ce6光敏剂自组装多功能诊疗一体化金属有机框架纳米材料的制备方法,以2-甲基咪唑为有机配体和Zn2+为金属离子,将掺钆硅(Si-Gd)纳米粒子和Ce6光敏剂加入反应体系一锅法快速合成了多功能诊疗一体化金属有机框架纳米粒子,负载药物后,在其表面修饰pH响应性PDMAEMA线性聚合物,再进一步修饰MaL-PEG-FA,包括如下步骤:
1)掺钆硅纳米粒子的制备,将柠檬酸三钠、二乙三胺五乙酸与GdCl3.H2O溶解在去离子水中,氩气保护下搅拌10-20min,加入3-氨丙基三乙氧基硅烷(APTES)继续搅拌20-30min,将反应物转移至高压反应釜中放入烘箱,180-200℃,2-3h后得到掺钆硅纳米粒子;
2)掺钆硅纳米粒子的纯化,待上述反应产物降至室温,向掺钆硅纳米粒子溶液中加入稀盐酸,将稀释后的产物转移至透析袋,透析过夜,得到纯化的掺钆硅纳米粒子(Si-GdNPs)溶液;
3)将纯化的掺钆硅纳米粒子用去离子水稀释,加入25mg/mL的聚乙烯吡咯烷酮-k30(PVP),在室温下反应12-24h,离心浓缩,制得PVP修饰的掺钆硅纳米粒子(Si-Gd@PVP);
4)将制备得到的Si-Gd@PVP溶液加入到ZnNO3甲醇溶液中,再将2-甲基咪唑溶液和Ce6溶液加入上述反应混合溶液中,磁力剧烈搅拌60-90min,离心,用甲醇和水清洗得到掺钆硅纳米粒子/Ce6掺杂的金属有机框架荧光纳米粒子(FZIF-8);
5)将制备的FZIF-8纳米粒子加入到盐酸阿霉素(DOX)溶液中吸附完全,清洗,得到负载有DOX的荧光金属有机框架纳米粒子(FZIF-8/DOX);
6)将制备的FZIF-8/DOX纳米粒子分散在去离子水中,加入制备好的聚甲基丙烯酸二甲氨基乙酯线性聚合物(PDMAEMA),室温条件下搅拌12-24h,用去离子水清洗得到PDMAEMA修饰的荧光金属有机框架纳米材料(FZIF-8/DOX-PD);
7)将制备的FZIF-8/DOX-PD纳米粒子分散在去离子水中,加入MaL-PEG-FA溶液,用氢氧化钠调节反应体系为pH=8.5,磁力搅拌反应8-12h,用去离子水清洗,得到MaL-PEG-FA修饰的诊疗一体化金属有机框架纳米材料(FZIF-8/DOX-PD-FA)。
2.根据权利要求1所述掺钆硅纳米粒子/Ce6光敏剂自组装的多功能诊疗一体化金属有机框架纳米材料的制备方法,其特征在于:步骤1)所述柠檬酸三钠、二乙三胺五乙酸、GdCl3.H2O、3-氨丙基三乙氧基硅烷用量比为:0.4-0.42g:0.3-0.32g:0.2-0.22g:2-2.2mL。
3.根据权利要求1所述掺钆硅纳米粒子/Ce6光敏剂自组装的多功能诊疗一体化金属有机框架纳米材料的制备方法,其特征在于:步骤2)所述掺钆硅纳米粒子溶液与稀盐酸体积比例为:8mL:6-7mL,盐酸的浓度为1mol/L。
4.根据权利要求1所述掺钆硅纳米粒子/Ce6光敏剂自组装的多功能诊疗一体化金属有机框架纳米材料的制备方法,其特征在于:步骤3)所述纯化的掺钆硅纳米粒子溶液、聚乙烯吡咯烷酮-k30体积比例为:10-12mL:4-6mL。
5.根据权利要求1所述掺钆硅纳米粒子/Ce6光敏剂自组装的多功能诊疗一体化金属有机框架纳米材料的制备方法,其特征在于:步骤4)所述ZnNO3溶液、2-甲基咪唑溶液、Si-Gd@PVP溶液、Ce6溶液的体积比例为:30-31mL:30mL:0.5-6mL:0.2-3mL,所述ZnNO3溶液浓度为14.6mg/mL,2-甲基咪唑溶液浓度为32.4mg/mL。
6.根据权利要求1所述掺钆硅纳米粒子/Ce6光敏剂自组装的多功能诊疗一体化金属有机框架纳米材料的制备方法,其特征在于:步骤5)所述掺钆硅纳米粒子/Ce6掺杂的金属有机框架双荧光纳米粒子(FZIF-8)、DOX溶液比例为:2mg:5-10mL,所述DOX的浓度为0.2mg/mL。
7.根据权利要求1所述掺钆硅纳米粒子/Ce6光敏剂自组装的多功能诊疗一体化金属有机框架纳米材料的制备方法,其特征在于:步骤6)所述负载有DOX的荧光金属有机框架纳米粒子(FZIF-8/DOX)与聚甲基丙烯酸二甲氨基乙酯线性聚合物(PDMAEMA)的比例为50mg:5-10mg。
8.根据权利要求1所述掺钆硅纳米粒子/Ce6光敏剂自组装的多功能诊疗一体化金属有机框架纳米材料的制备方法,其特征在于:步骤7)所述FZIF-8/DOX-PD纳米粒子与MaL-PEG-FA的比例为:50mg:6-10mg。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910541710.8A CN110227157A (zh) | 2019-06-21 | 2019-06-21 | 掺钆硅纳米粒子/光敏剂自组装金属有机框架纳米材料的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910541710.8A CN110227157A (zh) | 2019-06-21 | 2019-06-21 | 掺钆硅纳米粒子/光敏剂自组装金属有机框架纳米材料的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110227157A true CN110227157A (zh) | 2019-09-13 |
Family
ID=67857062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910541710.8A Pending CN110227157A (zh) | 2019-06-21 | 2019-06-21 | 掺钆硅纳米粒子/光敏剂自组装金属有机框架纳米材料的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110227157A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111467491A (zh) * | 2020-04-24 | 2020-07-31 | 东南大学 | 铂修饰MOF 2-Pt-FA作为双向增强光动力治疗药物的合成及在肿瘤治疗中的应用 |
CN112755183A (zh) * | 2019-11-04 | 2021-05-07 | 华中科技大学 | 一种有机金属框架纳米材料、其制备和应用 |
CN117138055A (zh) * | 2023-06-02 | 2023-12-01 | 中山大学附属第一医院 | 一种双载体的阿霉素载药纳米材料及其制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105271266A (zh) * | 2015-10-21 | 2016-01-27 | 哈尔滨工程大学 | 核壳结构的Gd-Si-Ce6多功能介孔纳米复合材料的制备方法 |
CN106362146A (zh) * | 2016-08-10 | 2017-02-01 | 福州大学 | 一种zif‑8@酞菁锌复合材料的制备及其应用 |
CN106512023A (zh) * | 2016-12-02 | 2017-03-22 | 武汉理工大学 | 双功能介孔硅球复合靶向给药***的制备方法 |
CN107596391A (zh) * | 2017-11-09 | 2018-01-19 | 上海纳米技术及应用国家工程研究中心有限公司 | 金属有机框架基纳米诊疗探针的制备方法及其产品和应用 |
CN108619511A (zh) * | 2018-04-20 | 2018-10-09 | 山东大学 | 一种基于阿糖胞苷小分子前药的金属有机框架载药***的制备方法和应用 |
CN108815523A (zh) * | 2018-07-05 | 2018-11-16 | 中国人民解放军第二军医大学第二附属医院 | 一种新型介孔硅球共载药纳米复合物及其制备方法 |
CN109172587A (zh) * | 2018-09-07 | 2019-01-11 | 上海大学 | 一种pH响应双药物释放的金属有机框架-上转换纳米体系的制备方法与应用 |
WO2019028250A1 (en) * | 2017-08-02 | 2019-02-07 | The University Of Chicago | NOMOGENEOUS ORGANOMETALLIC ORGANOMETRIC ORGANOMETRIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF |
CN109512797A (zh) * | 2018-12-21 | 2019-03-26 | 上海纳米技术及应用国家工程研究中心有限公司 | 基于金属有机框架的纳米药物载体的制备方法及其产品 |
-
2019
- 2019-06-21 CN CN201910541710.8A patent/CN110227157A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105271266A (zh) * | 2015-10-21 | 2016-01-27 | 哈尔滨工程大学 | 核壳结构的Gd-Si-Ce6多功能介孔纳米复合材料的制备方法 |
CN106362146A (zh) * | 2016-08-10 | 2017-02-01 | 福州大学 | 一种zif‑8@酞菁锌复合材料的制备及其应用 |
CN106512023A (zh) * | 2016-12-02 | 2017-03-22 | 武汉理工大学 | 双功能介孔硅球复合靶向给药***的制备方法 |
WO2019028250A1 (en) * | 2017-08-02 | 2019-02-07 | The University Of Chicago | NOMOGENEOUS ORGANOMETALLIC ORGANOMETRIC ORGANOMETRIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF |
CN107596391A (zh) * | 2017-11-09 | 2018-01-19 | 上海纳米技术及应用国家工程研究中心有限公司 | 金属有机框架基纳米诊疗探针的制备方法及其产品和应用 |
CN108619511A (zh) * | 2018-04-20 | 2018-10-09 | 山东大学 | 一种基于阿糖胞苷小分子前药的金属有机框架载药***的制备方法和应用 |
CN108815523A (zh) * | 2018-07-05 | 2018-11-16 | 中国人民解放军第二军医大学第二附属医院 | 一种新型介孔硅球共载药纳米复合物及其制备方法 |
CN109172587A (zh) * | 2018-09-07 | 2019-01-11 | 上海大学 | 一种pH响应双药物释放的金属有机框架-上转换纳米体系的制备方法与应用 |
CN109512797A (zh) * | 2018-12-21 | 2019-03-26 | 上海纳米技术及应用国家工程研究中心有限公司 | 基于金属有机框架的纳米药物载体的制备方法及其产品 |
Non-Patent Citations (5)
Title |
---|
JIAO-TONG SUN ET AL: ""Fabrication of PDEAEMA-Coated Mesoporous Silica Nanoparticles and pH-Responsive Controlled Release"", 《J. PHYS. CHEM. C》 * |
SI LI ET AL: ""One-pot hydrothermal preparation of gadolinium-doped silicon nanoparticles as a dual-modal probe for multicolor fluorescence and magnetic resonance imaging"", 《J. MATER. CHEM. B》 * |
YA-TING QIN ET AL: ""pH-Responsive Polymer-Stabilized ZIF‑8 Nanocomposites for Fluorescence and Magnetic Resonance Dual-Modal Imaging-Guided Chemo-/Photodynamic Combinational Cancer Therapy"", 《ACS APPL. MATER. INTERFACES》 * |
ZHONGXI XIE ET AL: ""O2‑Loaded pH-Responsive Multifunctional Nanodrug Carrier for Overcoming Hypoxia and Highly Efficient Chemo-Photodynamic", 《CHEM. MATER》 * |
郑晓鹏 等: ""荧光上转换纳米材料在光动力学治疗癌症中的应用"", 《中国肿瘤临床》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112755183A (zh) * | 2019-11-04 | 2021-05-07 | 华中科技大学 | 一种有机金属框架纳米材料、其制备和应用 |
CN112755183B (zh) * | 2019-11-04 | 2021-12-17 | 华中科技大学 | 一种有机金属框架纳米材料、其制备和应用 |
CN111467491A (zh) * | 2020-04-24 | 2020-07-31 | 东南大学 | 铂修饰MOF 2-Pt-FA作为双向增强光动力治疗药物的合成及在肿瘤治疗中的应用 |
CN117138055A (zh) * | 2023-06-02 | 2023-12-01 | 中山大学附属第一医院 | 一种双载体的阿霉素载药纳米材料及其制备方法 |
CN117138055B (zh) * | 2023-06-02 | 2024-04-16 | 中山大学附属第一医院 | 一种双载体的阿霉素载药纳米材料及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110227157A (zh) | 掺钆硅纳米粒子/光敏剂自组装金属有机框架纳米材料的制备方法 | |
Li et al. | A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity | |
CN106267204B (zh) | 一种黑磷纳米片-抗肿瘤化合物的复合材料及其制备方法和应用 | |
Bagheri et al. | Controlled direct growth of polymer shell on upconversion nanoparticle surface via visible light regulated polymerization | |
Hong et al. | Intense red-emitting upconversion nanophosphors (800 nm-driven) with a core/double-shell structure for dual-modal upconversion luminescence and magnetic resonance in vivo imaging applications | |
CN105903016B (zh) | 一种近红外光激发超分子阀门光控释药的核壳结构药物载体的制备方法 | |
CN107412195A (zh) | 一种pH响应的抗肿瘤药物载体材料及其制备和应用 | |
CN105214095B (zh) | 金属有机框架介孔结构的多功能纳米材料及制备方法 | |
CN109589418A (zh) | 一种具有pH响应性的席夫碱共聚物包覆的介孔二氧化硅载药纳米粒子及其制备方法和应用 | |
CN102078617B (zh) | 一种镶嵌金纳米棒的介孔硅基纳米复合材料的合成方法 | |
Wen et al. | In situ formation of homogeneous tellurium nanodots in paclitaxel-loaded MgAl layered double hydroxide gated mesoporous silica nanoparticles for synergistic chemo/PDT/PTT trimode combinatorial therapy | |
Chen et al. | Protonated 2D carbon nitride sensitized with Ce6 as a smart metal-free nanoplatform for boosted acute multimodal photo-sono tumor inactivation and long-term cancer immunotherapy | |
Liu et al. | Smart “on-off” responsive drug delivery nanosystems for potential imaging diagnosis and targeted tumor therapy | |
CN110819339B (zh) | Cu-氨基酸复合上转换纳米材料及其制备方法 | |
CN108310388A (zh) | 二硫键功能化的荧光介孔二氧化硅纳米颗粒的制备方法及其用途 | |
Liu et al. | Dual-path modulation of hydrogen peroxide to ameliorate hypoxia for enhancing photodynamic/starvation synergistic therapy | |
Pu et al. | Green synthesis of highly dispersed ytterbium and thulium co-doped sodium yttrium fluoride microphosphors for in situ light upconversion from near-infrared to blue in animals | |
Sun et al. | A facile approach to carbon dots‐mesoporous silica nanohybrids and their applications for multicolor and two‐photon imaging guided chemo‐/photothermal synergistic oncotherapy | |
Hou et al. | Full-active Cu2O/drug core/shell nanoparticles based on “grafting from” drug coordination polymerization combined with PD-1 blockade for efficient cancer therapy | |
CN110169958A (zh) | 一种基于荧光硅纳米粒子的多功能介孔二氧化硅复合纳米材料的制备方法 | |
CN106581683B (zh) | 一种聚乙二醇修饰的金属有机纳米材料及其制备方法、应用 | |
Liu et al. | Dual-responsive nanomotors for deep tumor penetration and subcellular arrangement | |
He et al. | Intelligent manganese dioxide nanocomposites induce tumor immunogenic cell death and remould tumor microenvironment | |
CN104147608B (zh) | 一种聚乙二醇‑叶酸修饰的氨基化锂皂石纳米颗粒及其制备和应用 | |
He et al. | Nanomedicine-based multimodal therapies: Recent progress and perspectives in colon cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190913 |
|
WD01 | Invention patent application deemed withdrawn after publication |